Study details
Enrolling now
Glecaprevir/Pibrentasvir Trial for PTSD
White River Junction Veterans Affairs Medical Center
NCT IDNCT05637879ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2/3
Target enrollment
92
Study length
about 2.8 years
Ages
19–70
Locations
1 site in VT
About this study
Researchers are testing glecaprevir/pibrentasvir, a medication, to see if it helps with Post-traumatic Stress Disorder (PTSD). The trial will last 1017 days and involve approximately 92 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Glecaprevir/pibrentasvir
PhasePhase 2/Phase 3
DrugGlecaprevir
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
Antiviral Agent [TC] (Breast Cancer Resistance Protein Inhibitors)
Body systems
Psychiatry / Mental Health